P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

P‐tau235: a novel biomarker for staging preclinical Alzheimer’s disease

Abstract Alzheimer’s disease (AD) is characterised by a long preclinical phase. Although phosphorylated tau (p‐tau) species such as p‐tau217 and p‐tau231 provide accurate detection of early pathological changes, other biomarkers capable of staging disease progression during preclinical AD are still...

Full description

Saved in:
Bibliographic Details
Main Authors: Juan Lantero‐Rodriguez, Anniina Snellman, Andrea L Benedet, Marta Milà‐Alomà, Elena Camporesi, Laia Montoliu‐Gaya, Nicholas J Ashton, Agathe Vrillon, Thomas K Karikari, Juan Domingo Gispert, Gemma Salvadó, Mahnaz Shekari, Christina E Toomey, Tammaryn L Lashley, Henrik Zetterberg, Marc Suárez‐Calvet, Gunnar Brinkmalm, Pedro Rosa Neto, Kaj Blennow
Format: Article
Language:English
Published: Springer Nature 2021-11-01
Series:EMBO Molecular Medicine
Subjects:
Alzheimer’s disease
biomarkers
CSF
p‐tau235
tau
Online Access:https://doi.org/10.15252/emmm.202115098
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.202115098

Similar Items